6results about How to "High anticancer activity" patented technology

The invention discloses a bispecific antibody targeting CD3 and PD-L1 and an application of the bispecific antibody. The bispecific antibody comprises a first antigen binding region, a second antigen binding region and an Fc part, the Fc part comprises a first Fc peptide fragment and a second Fc peptide fragment; the first antigen binding region comprises an scFv fragment and a binding protein of a first molecule or a fragment thereof, the binding protein of the first molecule or the fragment thereof is connected with the N end of the scFv fragment, and the C end of the scFv fragment is connected with the N end of the first Fc peptide fragment; the second antigen binding region comprises a binding protein of a second molecule or a fragment thereof, and the binding protein of the second molecule or the fragment thereof is connected with the N end of the second Fc peptide fragment; the first molecule and the second molecule are PD-L1, and the scFv fragment has CD3 binding activity. The bispecific antibody disclosed by the invention is good in safety, high in anti-cancer activity and high in clinical application and drug development value.

The invention relates to tripterine-luteolin-based self-assembled nanoparticles as well as a preparation method and application thereof, and belongs to the field of biological medicines. Compared with single tripterine, the tripterygium wilfordii derivative nano-particles provided by the invention have a stronger inhibition effect on tumor cells and lower toxicity, and have a good application prospect in the development of antitumor drugs.

The application belongs to the technical fields of medicinal chemistry and antitumor drugs, and discloses a polypeptide with anticancer activity, a preparation method and application thereof. The polypeptide is a Bathiapeptide F analogue containing a thiazole or dithiazole skeleton, and the molecular structure of the polypeptide contains independently changeable amino acid residue or peptide residue substituents. The application designs and synthesizes a new polypeptide analogue containing a thiazole or dithiazole skeleton by taking Bathiapeptide F as a parent structure. The preparation method includes the steps of amination reaction, sulfuration reaction, thiazole ring formation reaction, amide condensation reaction, ester hydrolysis, and removal of an amino protecting group. Experimental results show that the polypeptide has obvious inhibitory effect on Huh7 liver cancer cells, MDA-MB-231 breast cancer cells and A375 melanoma cells, and can be used for preparing anticancer drugs, and has good drug development prospects.

The application discloses a preparation method of diterpenoid compounds and application thereof. Ten diterpenoid compounds are separated from Euphorbia fischeriana, including six kinds of atisine type diterpenoid compounds, two kinds of gansuine type diterpenoid compounds, one kind of taxodine type diterpenoid compound and one kind of sequirine type diterpenoid compound. The diterpenoid compounds have the effect of promoting apoptosis of SW1990 pancreatic cancer cells, wherein the anticancer activity of compounds 1, 3 and 9 is better than that of positive drug paclitaxel, and the compounds can be used as leading compounds of anti-pancreatic cancer drugs, and also provide a basis and a new idea for extraction and medicinal research of the diterpenoid compounds.

This invention belongs to the field of pharmaceutical technology, specifically relating to a tetravalent platinum complex based on cinnamic acid, its preparation method, and its application. This invention is the first to introduce a cinnamic acid group into the structure of a tetravalent platinum complex, designing and synthesizing a series of novel platinum-based anticancer prodrugs, namely cinnamic acid-platinum (IV) complexes. Biological evaluation shows that these complexes exhibit stronger anticancer activity than classic divalent platinum drugs and good selectivity for cancer cells, demonstrating the potential of highly effective, low-toxicity, and drug-resistant novel anticancer drugs.

This invention belongs to the field of pharmaceutical research technology, specifically relating to a marine cyclic peptide, its synthesis method, and its uses. The structural formula of the marine cyclic peptide is shown in Formula I. Compared with natural Galaxamide, the Galaxamide analog containing D-leucine provided by this invention exhibits a greater inhibitory effect on human cancer cells, and the more D-leucines introduced, the stronger the anticancer activity. Simultaneously, by replacing one of the L-leucines in Galaxamide with other amino acids, the synthesized Galaxamide derivative is more effective than natural Galaxamide and has the potential to inhibit the proliferation of human cancer cell lines HepG2, U87, and MCF-7.